July 20, 2018
Add to Twitter
English | عربي
New Analysis of Rekovelle® Data Further Supports Use of AMH to Personalise Fertility Treatment
• Rekovelle’s unique dosing algorithm, which is based on a woman’s anti-Müllerian hormone (AMH) level and body weight, is designed for predictable ovarian response

• New analysis shows that natural variations in a woman’s AMH levels have no clinically relevant impact on ovarian response when using AMH to dose Rekovelle

• New analysis reinforces that AMH measured on any day of a woman’s menstrual cycle can be used to determine her daily dose of Rekovelle